

MANUELA CARUGATI

ri

ATTUALE POSIZIONE LAVORATIVA

Professore Associato, Transplant Infectious Diseases Service, Division of Infectious Diseases and International Health, Department of Medicine, Duke University (North Carolina, United States of America).

Dal Febbraio 2021 rivesto il ruolo di Professore Associato nella Divisione di Malattie Infettive di Duke University (Durham, US) (<https://medicine.duke.edu/faculty/manuela-carugati-md>). In questa posizione svolgo attività clinica, di ricerca, educativa, ed amministrativa presso il Centro Trapianti di Duke University. Il centro trapianti di Duke University è caratterizzato da alti volumi [più di 10,000 trapianti di organo solido effettuati] e grande complessità trapiantologica [sette programmi trapianto organo solido (cuore, polmone, fegato, rene, intestino, multi-organo), in aggiunta a programma trapianto cellule staminali e midollo]. La mia attività clinica ruota intorno alla cura di pazienti immunocompromessi per trapianto o patologia onco-ematologica. Oltre ad essere un clinico dedicato alla cura di pazienti immunocompromessi, mi occupo di ricerca clinica e traslazionale. A questo proposito, dirigo i programmi di ricerca di Duke University circa infezioni invasive del sito chirurgico in pazienti trapiantati di organo solido e circa infezioni di ventricolare assist devices (VAD). Da un punto di vista educativo, mi dedico alla formazione clinica e di ricerca di specializzandi di medicina interna, malattie infettive e farmacia. Da ultimo, la mia attività amministrativa si declina nell'essere parte del comitato di co-management del Centro Trapianti di Duke University (dove sono responsabile di molteplici quality improvement projects) e nel

PRECEDENTI
ESPERIENZE

dirigere le attività di Prevenzione e Controllo delle Infezioni per i pazienti immunocompromessi.

Professore Assistente Aggiunto, Duke University, Department of Medicine, Division of Infectious Diseases and International Health, Transplant Infectious Diseases Service (North Carolina, United States of America).

Da Dicembre 2017 a Febbraio 2021

Attività di ricerca clinica non retribuita.

Dirigente medico, Unità Operativa Semplice Prevenzione e Sorveglianza Malattie Infettive, ATS Brianza (Lecco, Italia).

Da Dicembre 2019 a Febbraio 2021

Questo intervallo temporale ha coinciso con congedo per maternità.

Dirigente medico, Unità Operativa Complessa di Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milano, Italia).

Da Giugno 2018 a Dicembre 2019

Attività clinica e di ricerca prevalentemente a favore della popolazione immunocompromessa trapiantata di organo solido (polmone, fegato, e rene). Supervisione clinica per specializzandi di Malattie Infettive dell'Università Statale di Milano.

Medico libero professionista, Unità Operativa Complessa di Malattie Infettive, Ospedale San Gerardo, Università Milano Bicocca (Monza, Italia).

Da Agosto 2017 a Giugno 2018

Attività clinica a favore di popolazione immunocompetente ed immunocompromessa. Supervisione clinica per specializzandi di Malattie Infettive dell'Università Bicocca.

Research Associate, Duke University, Department of Medicine, Division of Infectious Diseases and International Health, Transplant Infectious Diseases Service (North Carolina, United States of America).

Da Gennaio 2016 a Giugno 2017

Attività di ricerca clinica presso Duke University (Durham, NC) e centro di ricerca di Duke University in Tanzania (Kilimajaro Christian Medical Center, Moshi, Tanzania). In questa sede, ho coordinato l'attività di ricerca di Duke University per gli studi INDITe (collaborazione internazionale finanziata da National Institute of Health, <https://reporter.nih.gov/project-details/9198933>) e SETA (finanziato da Bill & Melinda Gates Foundation). La coordinazione delle attività di ricerca ha implicato la gestione dei finanziamenti e del personale di studio (40 persone circa). In aggiunta, ho svolto attività clinica per pazienti ricoverati presso Kilimajaro Christian Medical Center ed attività formativa a favore di studenti di medicina e

specializzandi di medicina interna presso Kilimajaro Christian Medical Center.

EDUCAZIONE

Certificazione ECFMG / Educational Commission for Foreign Medical Graduates (United States of America) / Maggio 2016

Specializzazione in Malattie Infettive / Università degli Studi di Milano (Milano, Italia) / Maggio 2015 / Summa cum laude

Clinical Research Fellowship / Duke University (Durham, United States of America) / Novembre 2013

Laurea Magistrale in Medicina e Chirurgia / Università degli Studi di Milano (Milano, Italia) / Luglio 2009 / Summa cum laude

Maturita' classica / Liceo classico statale Alessandro Volta (Como, Italia) / Luglio 2003 / Summa

RICONOSCIMENTI

ECCMID Award / Società Italiana di Malattie Infettive e Tropicali (SIMIT) / 2018

Young Investigator Award / American Society of Tropical medicine and Hygiene (ASTMH) / 2017

Top reviewer for Clinical Microbiology and Infection / European Society of Clinical Microbiology and Infectious Diseases (ESCMID) / 2016

George McCracken Infectious Diseases Fellow Award / American Society of Microbiology (ASM) / 2014

Infectious Diseases Academy (IDA) Award / Società Italiana di Malattie Infettive e Tropicali (SIMIT) / 2010

ATTIVITA' EDITORIALE

Associate Editor / Medical Mycology
([https://academic.oup.com/mmy/pages/Editorial Board](https://academic.oup.com/mmy/pages/Editorial_Board)) / 2024

Reviewer / Clinical Infectious Diseases / American Journal of Transplantation / Transplantation / Transplant Infectious Diseases / Liver Transplantation / Clinical Microbiology and Infection / European Respiratory Journal / Chest / BMC Pulmonary Medicine

FINANZIAMENTI
RICERCA

Duke Clinical and Translational Science Award / Investigatore principale: Duke University / Grant number: UL1TR002553/ Agenzia responsabile del finanziamento: National Institute of Health (NIH) / 2024 / Obiettivi del progetto. Questo finanziamento NIH supporta la ricerca traslazionale condotta da Duke University e dal Centro Trapianti di Duke University. Questo finanziamento e' stato utilizzato per supportare la mia ricerca in merito ai fattori di rischio per infezioni invasive del sito chirurgico in pazienti sottoposti a trapianto di polmone.

Severe Typhoid in Africa (SETA) / Investigatore principale: John A. Crump / Grant number: OPP1161162 / Agenzia responsabile del finanziamento: Bill & Melinda Gates Foundation (BMGF) / Obiettivi del progetto. Questo studio vuole generare evidenze circa incidenza, gravita', complicazioni, e sequele a lungo termine delle salmonellosi invasive in Africa.

A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Blood Stream Infections due to Staphylococci / Investigatore principale: Vance G. Fowler / Grant number: NCT01191840 / Agenzia responsabile del finanziamento: National Institute of Health (NIH/NIAID) / Obiettivi del progetto. Questo studio vuole valutare sicurezza ed efficacia del ridurre la durata del trattamento per pazienti con batteriemie da *Staphylococcus aureus* e staphylococchi coagulase-negativi.

GRUPPI DI RICERCA

Ventricular Assist Device (VAD) Infections Research Group / Duke University / Dal 2024 co-dirigo il gruppo di ricerca sulle infezioni associate a 'ventricular assist devices' a Duke University. In questa posizione svolgo il ruolo di mentore in campo di ricerca per colleghi piu' giovani (junior faculty). La nostra coorte comprende 498 pazienti con Heartmate 3 LVAD. I primi risultati sono stati sottomessi per presentazione al congresso internazionale IDWeek 2025 (Hazard before the hardware? Bloodstream infections prior to implantation of durable left ventricular assist devices).

Transplant Surgical Site Infections Research Group / Duke University / Dal 2021 dirigo il gruppo di ricerca sulle infezioni del sito chirurgico a Duke University. Attualmente stiamo sviluppando una collaborazione internazionale di ricerca per l'applicazione di intelligenza artificiale nella sorveglianza e diagnosi di infezioni del sito chirurgico nella popolazione trapiantata di organo solido / Outputs accademici ad oggi: 6 pubblicazioni a primo nome.

Community-Acquired Pneumonia Organization (CAPO) / University of Louisville / Il gruppo di ricerca CAPO ha lo scopo di facilitare la ricerca internazionale nel campo delle polmoniti

acquisite in comunit . CAPO conta ricercatori da 30 nazioni e 130 istituzioni. Come membro CAPO, ho promosso uno studio sulla efficacia e sicurezza di de-escalation della terapia antimicrobica in pazienti batteriemici ospedalizzati con polmonite acquisita in comunit  (PMID 26115864). Per questo lavoro ho ricevuto George McCracken Infectious Diseases Fellow Award da American Society of Microbiology / Outputs accademici ad oggi: 2 pubblicazioni, di cui 1 a primo nome.

Global Initiative for methicillin-resistant *Staphylococcus aureus* pneumonia (GLIMP) network / Universit  degli Studi di Milano / Fin dalla creazione di GLIMP in 2015, sono stata membro attivo di questo gruppo di ricerca ed ho promosso la collaborazione da diverse istituzioni (Universit  degli Studi di Milano e Duke University) / Outputs accademici ad oggi: 8 pubblicazioni, di cui 2 a primo nome.

International Collaboration on Endocarditis (ICE) / Duke University / A partire dal 2012 ho collaborato strettamente con il gruppo di ricerca ICE, dirigendo due studi osservazionali (PMID 24080644 and 27527083) e coordinando il trial 'A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Blood Stream Infections due to Staphylococci' (NCT01191840) per Duke University. Outputs accademici ad oggi: 4 pubblicazioni, di cui 2 a primo nome.

Investigating Febrile Deaths in Tanzania (INDITe) / Duke University / A partire dal Giugno 2016 sono membro attivo dle gruppo di studio INDITe, finanziato da National Institute of Health con grant R01TW009237. In questo contest ho ricevuto Young Investigator Award dalla American Society of Tropical Medicine and Hygiene per il mio lavoro sulla predizione della mortalit  in adolescenti ed adulti con febbre in paesi a risorse limitate. Il gruppo di studio INDITe mi ha concesso di stabilire collaborazioni internazionali di grandi rilevanza, tra cui la collaborazione con US CDC Infectious Diseases Pathology Branch e con Universit  di Glasgow / Outputs accademici ad oggi: 8 pubblicazioni, di cui 1 a primo nome.

Bacterial zoonoses (BZ) working grup / Otago University / A partire dal Giugno 2016 sono membro attivo del gruppo di studio BZ, promosso da Otago University. BZ raccoglie ricercatori da 4 continenti e promuove studi di ricerca in campo di zoonosi batteriche / Outputs accademici ad oggi: 8 pubblicazioni, di cui 2 a primo nome.

ATTIVITA' DIDATTICA

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2024-2025 / Attivita' di formazione a favore di specializzandi di Malattie Infettive di Duke University / Ore annue di insegnamento: 20.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2023-2024 / Attivita' di formazione a favore di specializzandi di Malattie Infettive di Duke University ed a favore di visiting international fellows / Ore annue di insegnamento: 20.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2023-2024 / Attivita' di formazione a favore di specializzandi di Farmacia di Duke University / Ore annue di insegnamento: 4.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2023-2024 / Attivita' di formazione a favore di transplant coordinators di Duke University / Ore annue di insegnamento: 4.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2022-2023 / Attivita' di formazione a favore di specializzandi di Malattie Infettive di Duke University / Ore annue di insegnamento: 10.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2022-2023 / Attivita' di formazione a favore di specializzandi di Farmacia di Duke University / Ore annue di insegnamento: 4

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2022-2023 / Attivita' di formazione a favore di transplant coordinators di Duke University / Ore annue di insegnamento: 2.

Duke University / Department of Medicine, Division of Infectious Diseases and International Health / Anno accademico 2021-2022 / Attivita' di formazione a favore di specializzandi di Malattie Infettive di Duke University / Ore annue di insegnamento: 10.

Duke University / Global Health Institute / Public policy, global health, and leadership in pandemic course / Anno accademico 2019-2020 / Attivita' di formazione a favore di studenti del master di Global Health / Ore annue di insegnamento: 2.

Ospedale San Gerardo / Divisione di Malattie Infettive / 2018 / Lezione CME per specialisti di Malattie Infettive circa endocarditi infettive. Ore annue di insegnamento: 2.

Kilimajaro Christian Medical University College / Department of Medicine / Anno accademico 2017-2018 / Attività di formazione a favore di specializzandi di medicina interna di Kilimajaro Christian Medical University College / Ore annue di insegnamento: 12.

COMPENDIO DELLA CASISTICA CLINICA (TIPOLOGIA E VOLUMI)

Dal 1 Febbraio 2021 esercito la mia attività clinica presso il centro trapianti di Duke University (Duke University, Durham, North Carolina, US). Il centro trapianti di Duke University è caratterizzato da alti volumi [più di 10,000 trapianti di organo solido effettuati dal 1965 ad oggi] e grande complessità trapiantologica. A questo riguardo, il centro trapianti di Duke conta sette programmi trapianto organo solido (cuore, polmone, fegato, rene, intestino, multi-organo, mano), in aggiunta a programma trapianto cellule staminali e midollo. Il centro trapianti di Duke University è centro trapiantologico di eccellenza a livello nazionale ed internazionale, come dimostrato dalla ottima performance clinica (tra i migliori tassi di sopravvivenza post-trapianto negli US) e dalla forte attività di ricerca. Tra i risultati di ricerca più notevoli del centro trapianti di Duke University negli ultimi anni si segnala il trial clinico che ha dimostrato efficacia e sicurezza dell'utilizzo di donatori da morte circolatoria per trapianto di cuore (NEJM 2023; 388:2121-2131), ampliando in questo modo il bacino di potenziali donatori e ponendo rimedio alla penuria d'organi che limita l'accesso al trapianto di molti candidati.

La mia attività clinica ruota intorno alla cura di pazienti immunocompromessi per trapianto o patologia onco-ematologica. La mia attuale casistica include: i) pazienti trapiantati di organo solido (polmone, cuore, fegato, rene, intestino, e trapianti multi-organo); ii) pazienti con ventricular assist devices (utilizzati sia come strategia definitiva, sia come ponte a trapianto); iii) pazienti sottoposti a trapianto di cellule staminali e midollo; iv) pazienti immunodepressi per patologia onco-ematologica (tra cui pazienti trattati con CAR-T e con anticorpi bi-specifici). I pazienti trapiantati di organo solido rappresentano approssimativamente il 60% della mia popolazione. I pazienti trapiantati di cellule staminali e midollo insieme ai pazienti onco-ematologici non trapiantati rappresentano il 30% della mia popolazione. Infine, i pazienti con ventricular assist devices costituiscono il 10% della mia casistica clinica. Per quanto concerne i pazienti trapiantati, mi dedico alla loro cura sia nella fase pre-trapianto che nella fase post-trapianto. La cura nella fase pre-trapianto include valutazioni di idoneità trapiantologica in pazienti con problematiche infettive precedenti il trapianto, come ad esempio infezioni da patogeni multi-farmaco resistenti, malattia tubercolare latente, ed infezione da HIV. A questo riguardo, ho seguito pazienti con infezione da HIV sia nel contesto di trapianto di organi addominali (rene e fegato), che nel contesto di trapianto di organi toracici (cuore e polmone), dove l'esperienza internazionale è estremamente esigua (risultati presentati a 44th International Society Heart and Lung Transplantation annual meeting, Praga, Aprile 2024 e pubblicati su Journal of Heart and Lung Transplantation Open <https://doi.org/10.1016/j.jhlto.2025.100238>). La mia attività clinica si estende anche alla valutazione infettivologica dei donatori. A questo riguardo, segnalo il lavoro clinico circa l'utilizzo di donatori HBsAg e HBV NAAT positivi.

A partire da Febbraio 2021, per ogni anno solare la mia attività clinica è stata data da 1 ambulatorio settimanale dedicato a pazienti non ricoverati e da 16 settimane di consulenza dedicate a pazienti ricoverati. Riporto a seguire i dettagli delle mie prestazioni cliniche per il periodo Febbraio 2021 – Dicembre 2024 (Tabella 1). Sottolineo che nell'anno 2022 ho usufruito di congedo di maternità (3 mesi). Riporto inoltre gli indicatori di produttività relativi alla mia pratica clinica (Tabella 2) rilasciati Duke Health Performance Service.

Tabella 1. Volumi clinici sostenuti nel periodo Febbraio 2021 – Dicembre 2024.

	02/2021- 12/2021	01/2022- 12/2022	01/2023- 12/2023	01/2024- 12/2024	Totale
Consulenze per pazienti ricoverati, n	1488	1203	1384	1376	5451
Valutazioni ambulatoriali, n	133	174	295	346	948

Tabella 2. Indicatori di produttività clinica relativi agli anni fiscali 2023 e 2024 rilasciati da Duke Health Performance Service.

	Fiscal Year 2023 July June	Fiscal Year 2024 July June
Consulenze per pazienti ricoverati	2010 wRVUs	2350 wRVUs
Valutazioni ambulatoriali	237 wRVUs	497 wRVUs

wRVU* = work Relative Value Units

CORSI, CONGRESSI, CONVEGNI E SEMINARI IN QUALITA' DI UDITORE (SONO STATI QUI RIPORTATI SOLO GLI EVENTI PIU' RILEVANTI E RECENTI)

1. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Ilan Schwartz. Climate changes and invasive fungal infections. Maggio 2025. AMA PRA Category 1, credito CME 1.
2. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Helen Boucher. Advocacy for innovation. How to accelerate the development of new anti-infectives. Aprile 2025. AMA PRA Category 1, credito CME 1.
3. American Society of Transplantation. CMV management in solid organ transplantation. Insights and Challenges from the new 4th consensus guidelines. Speaker: Dr. Camille Kotton. Aprile 2025.
4. University of Washington. National HIV curriculum. Opportunistic infections: prevention. Aprile 2025. AMA PRA Category 1, crediti CME 1.5.
5. University of Alabama School of Medicine. National HIV curriculum. Antiretroviral medications and initial therapy. Aprile 2025. AMA PRA Category 1, crediti CME 1.5.
6. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Gennaio-Maggio 2025. AMA PRA Category 1, crediti CME 10.
7. Duke University (Durham, US). Department of Medicine, LEAD conference. Speaker: Dr. Micah McClain. Febrile illnesses in a warming world: updates on tickborne diseases in NC. April 2025. AMA PRA Category 1, credito CME 1.
8. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Ahmad Mourad. Navigating the role, challenges, and future of international medical graduates in infectious diseases. Febbraio 2025. AMA PRA Category 1, credito CME 1.
9. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Madeleine Heldman. Reframing stewardship in the approach to post-transplant CMV infections. Febbraio 2025. AMA PRA Category 1, credito CME 1.
10. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Jonathan Huggins. CAR-T associated infections. Gennaio 2025. AMA PRA Category 1, credito CME 1.
11. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Erica Wilson. Reportable conditions and public health. Gennaio 2025. AMA PRA Category 1, credito CME 1.
12. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Gennaio-Dicembre 2024. AMA PRA Category 1, crediti CME 10.
13. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Erin Gettler. Impact of race, ethnicity, and social determinants of health on healthcare-associated infections. Dicembre 2024. AMA PRA Category 1, credito CME 1.
14. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Mehri McKellar. Perinatal HIV in the US. Dicembre 2024. AMA PRA Category 1, credito CME 1.
15. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Rebekah Moehring. Antimicrobial stewardship at transition of care. Novembre 2024. AMA PRA Category 1, credito CME 1.
16. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Amy Cornelli. Using qualitative research to advance HIV prevention and treatment. Novembre 2024. AMA PRA Category 1, credito CME 1.
17. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Dr. Christopher Shoff. Emerging diseases in the Americas. Novembre 2024. AMA PRA Category 1, credito CME 1.

18. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Jason E. Stout. The death project. Novembre 2024. AMA PRA Category 1, credito CME 1.
19. National Consortium for Data Science (NCDS). University of North Carolina at Chapel Hill. Foundations of AI: AI for Non-Coders. Settembre 2024.
20. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Nicholas Turner. Dalbavancin as an Option for the Treatment of Staphylococcus aureus Bacteremia: Results from the DOTS Trial. Luglio 2024. AMA PRA Category 1, credito CME 1.
21. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Michael G. Ison. Advancing the Field of Transplant Infectious Diseases: A Personal Journey from bedside to NIAID. Maggio 2024. AMA PRA Category 1, credito CME 1.
22. Duke University (Durham, US). Duke Transplant Center, Transplant Infectious Diseases Symposium. Next generation diagnostics in the immunocompromised host. AMA PRA Category 1, crediti CME 4.5
23. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Charles Hicks. Aprile 2024. AMA PRA Category 1, credito CME 1
24. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Sarah Dunstan. TB and genomics: a journey through Asia. Aprile 2024. AMA PRA Category 1, credito CME 1
25. Duke University (Durham, US). Duke Transplant Center, Grand Round. Developing a new LDLT program in the US and maintain quality with low volumes. Seminario. Marzo 2024. AMA PRA Category 1, credito CME 1
26. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Marzo 2024. AMA PRA Category 1, crediti CME 1.
27. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Sofia Zavala Monzon. The Utility of Geographic Information Systems in Tuberculosis Control. Febbraio 2024. AMA PRA Category 1, credito CME 1.
28. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: George R. Thompson. Coccidioidomycosis: what an ID doctor needs to know. Febbraio 2024. AMA PRA Category 1, credito CME 1.
29. Duke University (Durham, US). Department of Medicine, Duke Medicine Learning, Education, and Discussion Series. Speaker: Jason E. Stout. Tuberculosis. Gennaio 2024. AMA PRA Category 1, credito CME 1.
30. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Robert Rolfe. Vaccinations in international travelers. Gennaio 2024. AMA PRA Category 1, credito CME 1.
31. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimane. Gennaio-Dicembre 2023. AMA PRA Category 1, crediti CME 13.
32. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Milner Staub. Acknowledging and Addressing Gaps in Outpatient Stewardship. Dicembre 2023. AMA PRA Category 1, credito CME 1.
33. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Joel Gallant. Hot topics in HIV treatment. Dicembre 2023. AMA PRA Category 1, credito CME 1.
34. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Rebekah Moehering. Risk-adjustment for Comparisons of Hospital Antibiotic use: Where Are We Going. Dicembre 2023. AMA PRA Category 1, credito CME 1.
35. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Jason E. Stout. State of the state in TB. Seminario. Novembre 2023. AMA PRA Category 1, credito CME 1.
36. IDWeek 2023, Boston, Ottobre 2023.
37. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Gary Cox. Fever. Seminario. Settembre 2023. AMA PRA Category 1, credito CME 1.

38. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: David van Duin. Update on MDRO: Summary of AMR Guidance. Seminario. Settembre 2023. AMA PRA Category 1, credito CME 1.
39. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Sana Arif. Deciphering the role of infections in the development of allograft dysfunction. Seminario. Settembre 2023. AMA PRA Category 1, credito CME 1.
40. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Patrick Tam. (Molli)cute but deadly: Mycoplasma and Ureaplasma infections in lung transplant recipients. Seminario. Luglio 2023. AMA PRA Category 1, credito CME 1.
41. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Charles Burns. Pharmacist Driven PrEP: The Next Frontier. Seminario. Maggio 2023. AMA PRA Category 1, credito CME 1.
42. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Susanna Naggie. Got Decentralized Trials? What Can We Learn from ACTIV-6 to Inform the Future of Platform Trials in ID. Seminario. Aprile 2023. AMA PRA Category 1, credito CME 1.
43. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Jason E. Stout. Creating Early Opportunities for Clinical Research in ID Fellowship: What Can We Learn from the Mpox Outbreak. Seminario. Aprile 2023. AMA PRA Category 1, credito CME 1.
44. Duke University (Durham, US). Department of Medicine, Grand Round. Critical thinking applied to Infectious Diseases diagnostics. Seminario. Febbraio 2023. AMA PRA Category 1, credito CME 1.
45. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Gennaio-Dicembre 2022. AMA PRA Category 1, credito CME 9.
46. IDWeek 2022, Washington DC, Ottobre 2022
47. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Marta Mulawa. MASI: an ART adherence-supporting smartphone app for adolescents living with HIV in South Africa. Seminario. Maggio 2022. AMA PRA Category 1, credito CME 1.
48. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Jennifer L. Saullo. Updates in CMV Therapeutics and Experience in the DUH SOT Population. Seminario. Maggio 2022. AMA PRA Category 1, credito CME 1.
49. Duke University (Durham, US). Division of Hematology. Hematologic malignancies Grand Round. CLL and the CNS. Seminario. Maggio 2022. AMA PRA Category 1, credito CME 1.
50. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Charles Burns. Development and Implementation of a HIV re-engagement team at DUHS. Seminario. Maggio 2022. AMA PRA Category 1, credito CME 1.
51. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Cameron R. Wolfe. Seminario. Maggio 2022. AMA PRA Category 1, credito CME 1.
52. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Clare Smith. Seminario. Marzo 2022. AMA PRA Category 1, credito CME 1.
53. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Steve Taylor. Writing scientific manuscripts: A paint-by-numbers approach. Seminario. Marzo 2022. AMA PRA Category 1, credito CME 1.
54. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Thuy Lee. Seminario. Febbraio 2022. AMA PRA Category 1, credito CME 1.
55. Duke University (Durham, US). Duke Transplant Center, Core Curriculum. Seminario. Febbraio 2022. AMA PRA Category 1, credito CME 1.
56. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Febbraio-Dicembre 2021. AMA PRA Category 1, crediti CME 27.

57. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Emily Eichenberger. Bloodstream infections in solid organ transplant recipients. Seminario. Novembre 2021. AMA PRA Category 1, credito CME 1.
58. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Maria Blasi. HIV-1 and SARS-CoV-2 infection of the kidney. Seminario. Ottobre 2021. AMA PRA Category 1, credito CME 1.
59. Duke University (Durham, US). Duke Transplant Center, Grand Round. COVID and Transplant. Seminario. Settembre 2021. AMA PRA Category 1, credito CME 1.
60. Duke University (Durham, US). Department of Medicine, Grand Round. How to leave bias out of learner assessments and improve medical education in the process. Seminario. Luglio 2021. AMA PRA Category 1, credito CME 1.
61. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Sonali Advani. Novel approach to diagnostic stewardship: Upcoming changes to Urinalysis Reporting at DUHS. Seminario. Luglio 2021. AMA PRA Category 1, credito CME 1.
62. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Thomas Holland. Seminario. Luglio 2021. AMA PRA Category 1, credito CME 1.
63. Duke University (Durham, US). Duke Transplant Center, Grand Round. Pancreas transplantation for the recipient with cystic fibrosis. Seminario. Giugno 2021. AMA PRA Category 1, credito CME 1.
64. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Vivian H. Chu. A special recognition for Drs. Dan Sex and Claude Piantadosi. Seminario. Giugno 2021. AMA PRA Category 1, credito CME 1.
65. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Charles Burns. Multi-level Approach to Addressing the HIV Continuum of Care: Focus on Prevention and Re-Engagement. Seminario. Maggio 2021. AMA PRA Category 1, credito CME 1.
66. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Robert Rolfe. Improving representation of high-risk populations in the COVID-19 vaccine clinical trials and EUA implementation. Seminario. Maggio 2021. AMA PRA Category 1, credito CME 1.
67. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: John A. Crump. Nontyphoidal Salmonella invasive disease in Africa: current knowledge and data gaps. Seminario. Aprile 2021. AMA PRA Category 1, credito CME 1.
68. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speakers: Mihai Netea e Frank van de Veerdonk. Host-directed therapies in infectious diseases. Seminario. Aprile 2021. AMA PRA Category 1, credito CME 1.
69. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Gregory Gray. Mitigating future pandemics: new threats and strategies to consider. Seminario. Marzo 2021. AMA PRA Category 1, credito CME 1.
70. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Kristen Dicks. An update on clinical operations and opportunities. Seminario. Febbraio 2021. AMA PRA Category 1, credito CME 1.
71. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. Speaker: Becky Smith. Seminario. Febbraio 2021. AMA PRA Category 1, credito CME 1.
72. American Thoracic Society International Conference (ATS), Dallas, Maggio 2019
73. 28th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Aprile 2018.
74. 27th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Baltimore, Novembre 2017
75. 10th International Conference on Typhoid and Other Invasive Salmonellosis, Kampala, Aprile 2017.

76. 65th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Atlanta, Novembre 2016.
77. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Gennaio-Giugno 2015.
78. Infectious Diseases Society of America (IDSA), Hepatitis C Maintenance of Certification. Corso. 2015. 15 CME crediti.
79. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, Settembre 2014.
80. 24th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Barcellona, Maggio 2014.
81. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Gennaio-Novembre 2013.
82. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, Settembre 2013.
83. 23rd European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Berlino, April 2013.
84. Duke University (Durham, US). Division of Infectious Diseases, Case Conference. Seminario settimanale. Giugno-Dicembre 2012.
85. 22nd European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Londra, Aprile 2012.
86. 21st European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Milano, Maggio 2011
87. 17th Conference of Retroviruses and Opportunistic Infections (CROI), San Francisco, Febbraio 2010.

CORSI, CONGRESSI, CONVEGNI E SEMINARI IN QUALITA' DI RELATORE
(PRESENTAZIONI ORALI)

1. Duke University (Durham, US). Duke Institute of Health Innovation. 2025. Invited Presentation. **Carugati M.** Artificial intelligence for monitoring surgical site infections among lung transplant recipients.
2. Duke University (Durham, US). Department of Medicine Research Day. 2024. Seminario. Invited Presentation. **Carugati M.** Invasive surgical site infections after lung transplantation: risk factors and associated clinical outcomes at Duke University Hospital in the period 2017-2021.
3. Duke University (Durham, US). Transplant Center Strategy & Executive Oversight Meeting. 2024. Seminario. Invited Lecture. **Carugati M.** Risk factors for invasive primary surgical site infections (IP-SSI) occurring within 3 months from transplant surgery among single organ adult lung transplant recipients at Duke University Hospital.
4. Duke University (Durham, US). Transplant Center Strategy & Executive Oversight Meeting. 2024. Seminario. Invited Lecture. **Carugati M.** Implementation and down-stream effects of VRE screening among adult liver transplant candidates at Duke University Hospital.
5. Duke University (Durham, US). Division of Infectious Diseases, Transplant ID (TIDBITS) Meeting. Corso. 2024. Invited Lecture. **Carugati M.** Blastomycosis among solid organ transplant recipients.
6. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. 2024. Seminario. Invited Lecture. **Carugati M.** Invasive surgical site infections among thoracic organ transplants. 1 AMA PRA Category 1 credito CME.
7. ASST Papa Giovanni XXIII (Bergamo, Italia). 2024. Seminario. Invited Lecture. **Carugati M.** Beating the beasts. New armamentarium against CMV and non-tuberculous mycobacteria for immunocompromised hosts.
8. Duke University (Durham, US). Division of Infectious Diseases, Transplant ID (TIDBITS) Meeting. 2023. Corso. Invited Lecture. **Carugati M.** Refractory and resistant CMV.
9. Duke University (Durham, US). Division of Infectious Diseases, Transplant ID (TIDBITS) Meeting. 2023. Corso. Invited Lecture. **Carugati M.** Mycoplasma pneumoniae infections.
10. Duke University (Durham, US). Division of Infectious Diseases, Transplant ID (TIDBITS) Meeting. 2023. Corso. Invited Lecture. **Carugati M.** Mycobacterium abscessus and GATA-2 deficiency.
11. Humanitas University (Rozzano, Italia). 2023. Seminario. Invited Lecture. **Carugati M.** Lower respiratory tract infections in immunocompromised hosts.
12. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. 2023. Seminario. Invited Lecture. **Carugati M.** Echinocandin failure to prevent Candida surgical site infections. 1 AMA PRA Category 1 credito CME.
13. Duke University (Durham, US). Liver Transplant Retreat. 2023. Seminario. Invited Lecture. **Carugati M.** Risk factors for invasive surgical site infections among liver transplant recipients.
14. Duke University (Durham, US). Division of Infectious Diseases, Grand Round. 2022. Seminario. Invited Lecture. **Carugati M.** Surgical site infections in the Duke solid organ transplant population. 1 AMA PRA Category 1 credito CME.
15. Duke University (Durham, US). Hematologic malignancies Grand Round. 2022. Seminario. Invited Lecture. **Carugati M.** JC virus and progressive multifocal leukoencephalopathy. 1 AMA PRA Category 1 credito CME.
16. Duke University (Durham, US). Global Health Institute. Global Health Master Program. 2020. Corso. **Carugati M.** Sars-CoV-2 and the Italian response.
17. American Thoracic Society International Conference (Dallas, US). 2019. Congress oral presentation. **Carugati M.** Bacterial Etiology of Community-Acquired Pneumonia and

- Appropriateness of Empirical Treatment Recommendations: an International Observational Cohort Study.
18. 28th European Conference of Clinical Microbiology and Infectious Diseases (Madrid, Spagna). 2018. Congress oral presentation. **Carugati M.** Microbiological testing in adult inpatients with community-acquired pneumonia: an international, observational cohort study.
 19. 27th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting (Baltimore, US). 2017. Congress oral presentation. **Carugati M.** Predicting mortality for adolescent and adult patients with fever in resource-limited settings.
 20. Scientific Advisory Process for Optimal Research on Typhoid (SAPORT) meeting (Kampala, Uganda). 2017. Seminario. Invited Lecture. **Carugati M.** Tanzania febrile etiology study.
 21. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, US). 2014. Congress oral presentation. **Carugati M.** De-Escalation Therapy (DET) is Safe in Septic Patients with Community-Acquired Pneumonia (CAP).
 22. 24th European Conference of Clinical Microbiology and Infectious Diseases (Barcellona, Spagna). 2014. Congress oral presentation. **Carugati M.** Antistaphylococcal penicillins vs. glycopeptides in the treatment of infective endocarditis due to methicillin-susceptible coagulase-negative staphylococci. A prospective cohort study from the International Collaboration on Endocarditis (ICE).
 23. 23rd European Conference of Clinical Microbiology and Infectious Diseases (Berlino, Germania). 2013. Congress oral presentation. **Carugati M.** Daptomycin versus standard therapy for endocarditis caused by coagulase negative Staphylococci. The International Collaboration on Endocarditis Prospective Cohort Study.

CORSI, CONGRESSI, CONVEGNI E SEMINARI IN QUALITA' DI RELATORE (POSTERS)

1. World Transplant Congress 2025, San Francisco, Agosto 2025. Collis B, Heldman MR, Kothadia S, Maziarz E, Ni B, Huggins JP, **Carugati M**, Tam P, Seidenfeld A, Schwartz I, Wolfe CR, Saullo JL, Arif S, Reynolds JM, Baker AW. Management and Outcomes of Lung Transplant Recipients with Post-Transplant *Mycobacterium abscessus* complex Infection. Accepted.
2. IDWeek 2024, Los Angeles, Ottobre 2024. Seidelman J, Smith B, Arif S, Lewis SS, Gettler E, Baker AW, Padgett P, Wood B, Williams M, Fleming P, Schroder JN, Milano C, Miller RA, Alexander BD, **Carugati M**. A Change of Heart: Limitations of National Healthcare Safety Network (NHSN) and Society of Thoracic Surgeons (STS) Surveillance Systems in Identifying SSI After Heart Transplant Surgery.
3. IDWeek 2024, Los Angeles, Ottobre 2024. Steinbrick J, Mehdiratta N, Pena H, Welsby J, Seidenfeld A, **Carugati M**, Seidelman J. Optimizing Blood Culture Utilization in Solid Organ Transplant Recipients: A Diagnostic Stewardship Approach.
4. 30th International Congress of the Transplantation Society, Istanbul, Settembre 2024. Wolfe C, Antonia A, **Carugati M**, Heldman MR, Huggins J, Messina JA, Maziarz EK, Saullo JH, Schwartz IS, Steinbrink JM, Tam PCK, Baker AW. Cell-free DNA testing. A new arrow in the ID doctor's quiver? Or a stewardship nightmare?
5. 44th International Society Heart and Lung Transplantation (ISHLT) annual meeting, Praga, Aprile 2024. Heldman MR, Saullo JL, Menacham BM, Messina JA, Arif S, Steinbrink J, Tam PCK, **Carugati M**, Wolfe CR, Baker AW and Maziarz EK. Infections After Belatacept in Lung Transplant Recipients.
6. 44th International Society Heart and Lung Transplantation (ISHLT) annual meeting, Praga, Aprile 2024. Wolfe CR, Tam PCK, Steinbrink J, Messina JA, Bin N, Schwartz I, **Carugati M**, Devore A, Baker AW. HOPE for a bright future.
7. IDWeek 2023, Boston, Ottobre 2023. **Carugati M**, Arif S, King LY, Harris M, Evans K, Barbas AS, Sudan DL, Miller RA, Alexander BD. Risk Factors for Invasive Primary Surgical Site Infections among Single Adult Liver Transplants at Duke University in the Period 2015-2019.
8. 72nd American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Chicago, Ottobre 2023. Madut DB, Rubach MP, Boisen N, Gogry FA, Call DR, **Carugati M**, Kalengo N, Marandu A, Maze MJ, Morrissey AB, Lwezaula BF, Mmbaga BT, Kilonzo KG, Maro VP, Scheutz F, Crump JA. Genomic characterization of extraintestinal pathogenic *Escherichia coli* causing bloodstream infections among hospitalized patients in northern Tanzania.
9. 72nd American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Chicago, Ottobre 2023. Madut DB, Rubach MP, Boisen N, Costales C, **Carugati M**, Amsi PT, Mremi AR, Kalengo N, Mosha C, Marandu A, Maze MJ, Mmbaga BT, Kilonzo KG, Maro VP, Scheutz F, Crump JA. Evaluation of virulence gene repertoire as a mean to establish the role of *Escherichia coli* isolated post-mortem in the causal pathway to death, northern Tanzania.
10. 72nd American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Chicago, Ottobre 2023. Rolfe RJ, Rubach MP, Maro VP, Mmbaga BT, Lwezaula B, Kalengo N, Kinabo G, Mosha C, Marandu A, Mbwasia R, Kilonzo K, Lyamuya F, Bonnewell JP, **Carugati M**, Maze MJ, Madut DB, Ledermann JP, Burns PL, Beaver D, Powers AM, Crump JA. Arbovirus disease surveillance among febrile patients in Kilimanjaro, Tanzania, 2016- 2019.
11. 72nd American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Chicago, Ottobre 2023. Maze MJ, Shirima GM, Lukambagire AHS, Bodenham RF, Rubach MP, Cash-Goldwasser S, **Carugati M**, Thomas KM, Sakasaka P, Mkenda N, Allan KJ, Kazwala RR, Mmbaga BT, Buza JJ, Maro VP, Galloway RL, Haydon DT, Crump JA, Halliday JEB. Prevalence and risk factors for human leptospirosis in a pastoralist community, Endulen, Tanzania.

12. American Transplant Congress, San Diego, Giugno 2023. Evans K, Harris M, Lee H, F. Hung F, Wrenn R, **Carugati M**, Alexander BD. Antibacterial Prophylaxis Regimens In Adult Orthotopic Liver Transplantation And Incidence Of Post-operative Bacterial Infections.
13. American Transplant Congress, San Diego, Giugno 2023. Evans. Ni B, Wolfe C, Arif S, **Carugati M**, Heldman MJ, Messina JA, Miller RA, Saullo JL, Baker AW, Maziarz EK. Single-Center Experience with Maribavir for the Treatment of CMV Infection in Solid Organ Transplant Recipients.
14. 71st American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Seattle, Ottobre 2022. Moorthy GS, Madut DB, Kilonzo KG, Lwezaula BF, Mbwasia R, Mmbaga BT, Ngocho JS, Saganda W, Bonnewell JP, **Carugati M**, Egger JR, Hertz JT, Tillekeratne LG, Maze MJ, Maro VP, Crump JA, Rubach MP. Antibacterial utilization for febrile illnesses and laboratory-confirmed bloodstream infections in northern Tanzania.
15. 71st American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Seattle, Ottobre 2022. Ngocho J, Liu J, Kalengo NH, Kipengele AH, Kilonzo KG, Kinabo G, Lwezaula BF, Lyamuya F, Marandu A, Mbwasia R, Mmbaga BT, Mosha C, **Carugati M**, Madut DB, Bonnewell JP, Maze MJ, Maro VP, Crump JA, Houpt ER, Rubach MP. TaqMan Array Card multiplex PCR panel to detect pathogens in whole blood of febrile inpatients in northern Tanzania, 2016-2019.
16. 71st American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Seattle, Ottobre 2022. Madut DB, Rubach MP, Rolfe RJ, **Carugati M**, Bonnewell JP, Allan KJ, Glanville WA, Halliday JEB, Thomas KM, Kinabo GD, Mremi AR, Amsi PT, Kalengo NH, Lyamuya F, Lwezaula B, Mosha C, Marandu A, Maze MJ, Costales C, Mbwasia R, Kilonzo KG, Zhu F, Chia WN, Anderson D, Mmbaga BT, Maro VP, Liu J, Houpt ER, Wang L, Leach A, Patel K, Cleaveland S, Klena JD, Crump JA. Epidemiologic and genomic characterization of an outbreak of Rift Valley fever among humans and dairy cattle in northern Tanzania, 2018.
17. European Respiratory Society (ERS) International Congress, Settembre 2020. Pascual Guardia S, Marin-Corral J, **Carugati M**, Aliberti S, Sibila O, Sanz F, Sotgiu G, Marcos PJ, Kolditz M, Restrepo MI. International Guideline concordance of empiric antibiotic use in community-acquired pneumonia. ERS 2020. European Respiratory Journal 2020 56: 4669; DOI: 10.1183/13993003.congress-2020.4669
18. European Respiratory Society (ERS) International Congress, Settembre 2020. Restrepo MI, Pascual-Guardia S, Marin-Corral J, **Carugati M**, Rodriguez A, Sibila O, Sanz F, Sotgiu G, Kolditz M, Aliberti S, GLIMP Investigators. Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia. European Respiratory Journal 2020 56: 3094; DOI: 10.1183/13993003.congress-2020.3094
19. 6th World One Health Congress (WOHC), Novembre 2020. Halliday JEB, **Carugati M**, Snaveley ME, Allan KJ, Beamesderfer J, Ladbury GAF, Hoyle DV, Holland P, Crump JA, Cleaveland S, Rubach MP. Zoonotic causes of febrile illness in malaria endemic countries.
20. American Society for Microbiology (ASM) Microbe, Chicago, June 2020. Costales C, Crump JA, Mremi AR, Amsi PT, **Carugati M**, Madut D, Nelson AM, Maro VP, Rubach MP. Performance evaluation of the Xpert MTB/RIF Ultra assay on postmortem nasopharyngeal specimens to identify suspected and unsuspected tuberculosis deaths among hospitalized patients in northern Tanzania.
21. 68th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, National Harbor, Novembre 2019. Costales C, Rubach MP, Mremi A, Amsi P, **Carugati M**, Nelson AM, Maro VP, Crump JAC. Assessing the role of postmortem microbiology in determining the cause of fatal febrile illness, Kilimanjaro, Tanzania.
22. 68th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, National Harbor, Novembre 2019. Pisharody S, Rubach MP, Nicholson WL, Perniciaro JL, **Carugati M**, Biggs HM, Maze MJ, Hertz JT, Halliday JE, Allan KJ, Mmbaga BT, Saganda W, Lwezaula BF,

- Kazwala RR, Cleaveland S, Maro VP, Crump JA. Incidence of acute Q fever and spotted fever group rickettsioses, Kilimanjaro, Tanzania, 2007-2008 and 2012-2014.
23. 68th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, National Harbor, Novembre 2019. Cutting ER, Madut DB, Maze MJ, Kalengo NH, **Carugati M**, Mmbaga BT, Mbwasia RM, Kilonzo KG, Marandu A, Mosha C, Lyamuya FS, Kinabo GD, Morrissey AB, Maro VP, Rubach MP, Crump JA. Endemic typhoid incidence, Kilimanjaro Region, Tanzania, 2007-2018.
 24. American Thoracic Society International Conference (ATS), Dallas, Maggio 2019. Restrepo MI, Borsa N, **Carugati M**, Soni NJ, Rodriguez AH, Blasi F, Aliberti S; GLIMP collaborators. MRSA specific scores promote overuse of anti-MRSA antibiotics.
 25. 67th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, New Orleans, Novembre 2018. Madut DB, Rubach MP, Kalengo NH, **Carugati M**, Maze MJ, Morrissey AB, Mmbaga BT, Lwezaula BF, Kilonzo KG, Crump JA. Risk factors for *Escherichia coli* bacteremia among adolescent and adults in northern Tanzania.
 26. 67th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, New Orleans, Novembre 2018. Mmbaga BT, Mremi A, Amsi P, Manjira E, Kalengo N, **Carugati M**, Maro VP, Crump JA, Maugau L, Kondo C, Rubach MP. Etiologies of gastro-intestinal perforations in Kilimanjaro, Tanzania: prospective hospital-based sentinel surveillance.
 27. 65th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting, Atlanta, Novembre 2016. **Carugati M**, Biggs HM, Maze MJ, Stoddard RA, Cash-Goldwasser S, Hertz JT, Halliday JEB, Mmbaga BT, Saganda W, Lwezaula BF, Kazwala RR, Cleaveland S, Maro VP, Rubach MP, Crump JA. Incidence of Acute Brucellosis in the Kilimanjaro Region of Tanzania between 2007-2008 and 2012-2014.
 28. 24th Italian Society of Infectious and Tropical Diseases (SIMIT) Conference, Catania, November 2015. Monge E, Croce F, **Carugati M**, Zanini F, Morosi M, Oreni L, Schioli C, Franzetti F, Galli M. Clinical features and predictors of adverse outcome in acute meningitis in adults.
 29. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, Settembre 2013. **Carugati M**, Park L, del Rio A, Hannan M, Guimarães AC, Mirò JM, Chu VH and the ICE-PCS investigators. Decreased Vancomycin Susceptibility and Outcome in Patients with Coagulase Negative Staphylococci (CNS) Infective Endocarditis (IE). The International Collaboration on Endocarditis Prospective Cohort Study (ICE PCS). Poster E-141.
 30. 22nd European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Londra, Aprile 2012. Clinical Microbiology and Infection 2012; 18: s3: 441. **Carugati M**, Zanini F, Schioli C, Vanoni N, Tocalli L, Bucciarelli P, Galli M and Franzetti F. Risk factors of adverse outcome in HIV positive patients with bloodstream infections: an observational retrospective case control study in Milan. Poster.
 31. 22nd European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Londra, Aprile 2012. Clinical Microbiology and Infection 2012; s3: 510. Zanini F, **Carugati M**, Schioli C, Vanoni N, Lombardi A, Codecasa L, Gori A, Franzetti F. Clinical and molecular analysis of the distribution of the genotypic lineages of *Mycobacterium tuberculosis* clinical isolates in the immigrant population and in Italians in the urban area of Milan, 1994–2009. Poster.
 32. 21st European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Milano, Maggio 2011. Clinical Microbiology and Infection 2011, 17: S108 – S668. **Carugati M**, Zanini F, Schioli C, Croce F and Franzetti F. Respiratory isolation in HIV patients with supposed TB pulmonary infection: comparison of clinical predictive models. Poster.
 33. Italian Conference on AIDS and retroviruses (ICAR), Firenze, Marzo 2011. **Carugati M**, Zanini F, Schioli C, Tocalli L and Franzetti F. What about bacterial pneumonia after more than a decade of HAART?

34. Italian Conference on AIDS and retroviruses (ICAR), Firenze, Marzo 2011. Zanini F, **Carugati M**, Schiroli C, Lapadula G, Lombardi A, Mazzola E, Codecasa L, Gori A and Franzetti F. Multi drug resistant tuberculosis and human immunodeficiency virus infection in the urban setting of Milan (1996-2009): an awkward heritage of the recent past.
35. 20th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Aprile 2010. *Clinical Microbiology and Infection* 2010, 16: S133 – S634. Zanini F, **Carugati M**, Schiroli C, Lombardi A, Mazzola E, Codecasa L, Gori A and Franzetti F. *Mycobacterium tuberculosis* Beijing family strains: analysis of molecular typing and of the epidemiological and clinical factors associated with an emerging lineage in the urban setting of Milan (1996-2007). Poster.
36. 17th Conference of Retroviruses and Opportunistic Infections (CROI), San Francisco, Febbraio 2010. Motta D, Zanini F, Codecasa L, Ricci ED, Sabbatici F, Airolidi M, Franzetti F, **Carugati M**, Gori A, and Lapadula G. Changing Burden of HIV Infection on Tuberculosis Epidemic in the Metropolitan Area of Milan. Abstract 779, Session Poster.
37. 17th Italian Society of Infectious and Tropical Diseases (SIMIT) Conference, Bergamo, Novembre 2008. Zanini F, Gori A, Orlando G, Lombardi A, **Carugati M**, Bandiera A and Franzetti F. Extrapulmonary tuberculosis epidemiology: inpatient population from 1995 to 2007. Abstract 106.

PUBBLICAZIONI SCIENTIFICHE PEER-REVIEWED EDITE A STAMPA

1. **Carugati M**, Arif S, Reynolds JM, Haney JC, Yarrington ME, Young K, Kulkarni D, Benjamin A, Walline K, Huggins J, Rosser M, Morrison S, Peskoe S, Bottiger BA, Miller RA, Alexander BD. Invasive surgical site infections after lung transplantation: contemporary risk factors and associated clinical outcomes. *J Heart Lung Transplant Open* 2025. Accettato il 16 Maggio 2025 (JHLTO_100294).
2. A Change of Heart: Limitations of National Healthcare Safety Network (NHSN) and Society of Thoracic Surgeons (STS) Surveillance Strategies in Identifying Surgical Site Infections after Heart Transplant Surgery. Seidelman J, Smith B, Arif S, Lewis SS, Gettler EB, Baker AW, Padgett P, Wood B, Williams M, Fleming P, Schroder JN, Milano C, DeVore A, Miller RA, Alexander BD, **Carugati M**. *Am J Infect Control* 2025; S0196-6553(25)00289-5.
3. The Tell-Tale Hearts: Donor-Derived Invasive Fungal Infections among Orthotopic Heart Transplant Recipients. Krishnan J, **Carugati M**, Miller RA, Wolfe CR, Messina JA. *Med Myco Case Report* 2025. <https://doi.org/10.1016/j.mmcr.2025.100702>
4. Tam PCK, Messina JA, Bin N, Heldman MR, Steinbrink JM, Reynolds JM, DeVore AD, Baker AW, **Carugati M**, Schwartz IS, Wolfe CR. HOPE in every breath and heartbeat: Understanding transplant eligibility, access barriers, and clinical outcomes in thoracic transplantation in persons with HIV. *J Heart Lung Transplant Open* 2025, doi: <https://doi.org/10.1016/j.jhlto.2025.100238>
5. Monardo R, Arif S, Rege A, Simon E, Ledbetter L, Baker AW, Stout J, **Carugati M**. *Bacillus Calmette-Guérin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol*. *Syst Rev* 2025; 14: 21. doi: 10.1186/s13643-025-02761-y.
6. Ngocho JS, Liu J, Kalengo NH, Kipengele AH, Maro A, Mujage B, Senyael N, Gratz J, Kilonzo KG, Kinabo G, Lwezaula BF, Lyamuya F, Marandu A, Mbwasia R, Mmbaga BT, Mosha C, **Carugati M**, Madut DB, Bonnewell JP, Maze MJ, Maro VP, Crump JA, Houpt ER, Rubach MP. Taqman array card real-time polymerase chain reaction panel to detect pathogens in whole blood in febrile inpatients in Northern Tanzania, 2016-2019. *Trop Med Int Health* 2024. doi: 10.1111/tmi.14083.
7. Wolfe C, Antonia A, **Carugati M**, Heldman MR, Huggins J, Messina JA, Maziarz EK, Saullo JH, Schwartz IS, Steinbrink JM, Tam PCK, Baker AW. Cell-free DNA testing. A new arrow in the ID doctor's quiver? Or a stewardship nightmare? *Transplantation* 108(9S), doi: 10.1097/01.tp.0001065388.99937.1d
8. Madut DB, Rubach MP, Allan KJ, Thomas KM, de Glanville WA, Halliday JEB, Costales C, **Carugati M**, Robert J Rolfe RJ, Bonnewell JP, Maze MJ, Mremi AR, Amsi PT, Kalengo NH, Lyamuya F, Kinabo GD, Mbwasia R, Kilonzo KG, Maro VP, Mmbaga BT, Lwezaula B, Mosha C, Marandu A, Kibona TJ, Zhu F, Chawla T, Chia WN, Anderson DE, Wang LF, Liu J, Houpt ER, Martinez RB, Zaki SR, Leach A, Gibbons A, Chiang CF, Patel K, Klena JD, Cleaveland S, Crump JA. Epidemiologic and genomic characterization of an outbreak of Rift Valley fever among humans and dairy cattle in northern Tanzania. *J Infect Dis* 2024; doi:10.1093/infdis/jiae562.
9. Heldman MR, Saullo JL, Menacham BM, Messina JA, Arif S, Steinbrink J, Tam PCK, **Carugati M**, Wolfe CR, Baker AW and Maziarz EK. Epidemiology of Infections in Lung Transplant Recipients treated with belatacept. *Transplant Infectious Diseases* 2024:e14403.
10. Gutierrez-Villanueva A, Calderon-Parra J, Callejas-Diaz A, Munez-Rubio E, Velasquez K, Ramos-Martinez A, Rodriguez-Alfonso B, Fernandez-Cruz A, **Carugati M**, et al. What do we know about FDG-PET-CT for the management of invasive fungal infections? An international survey. *Mycopathologia* 2024; 189:84.
11. **Carugati M**, Arif S, Yarrington ME, King LY, Harris M, Evans K, Barbas AS, Sudan DL, Miller RA, Alexander BD. Risk Factors for Invasive Surgical Site Infections among Adult Single Liver

- Transplant Recipients at Duke University Hospital in the Period 2015-2020. *Transplantation Direct* 2024. 10.1097/TXD.0000000000001719.
12. Ni B, Wolfe CR, Arif S, **Carugati M**, Heldman MR, Messina JA, Miller RA, Saullo JL, Baker AW, Maziarz EK. Real-World Experience with Maribavir for the Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. *Open Forum Infect Dis* 2024; 11 (7): ofae335.
 13. **Carugati M**, Arif S, Sudan DL, Collins BH, Haney JC, Schroder JN, Reynolds JM, Lewis SS, Yarrington ME, Miller RA, Alexander BD. Late Surgical Site Infections among Solid Organ Transplant Recipients: An Unrecognized Clinical Entity. *Infection Prevention and Control* 2024; 24: 1-5.
 14. **Carugati M**, Arif S, Yarrington ME, King LY, Harris M, Evans K, Barbas AS, Sudan DL, Perfect JR, Miller RA, Alexander BD. Limitations of Antifungal Prophylaxis in Preventing Invasive *Candida* Surgical Site Infections after Liver Transplant Surgery. *Antimicrobial Agents and Chemotherapy* 2024; 68 (3): e0127923.
 15. Hagedoorn NN, Maze MJ, **Carugati M**, Cash-Goldwasser S, Allan KJ, Chen K, Cossic B, Demeter E, Gallagher S, German R, Galloway RL, Habuš J, Rubach MP, Shiokawa K, Sulikhan N, Crump JA. Global distribution of *Leptospira* serovar isolations and detections from animals: a systematic review. *Tropical Medicine and International Health* 2024; 29 (3): 161-172.
 16. Maze MJ, Shirima GM, Lukambagire AHS, Bodenham RF, Rubach MP, Cash-Goldwasser S, **Carugati M**, Thomas KM, Sakasaka P, Mkenda N, Allan KJ, Kazwala RR, Mmbaga BT, Buza JJ, Maro VP, Galloway RL, Haydon DT, Crump JA, Halliday JEB. Prevalence and risk factors for human leptospirosis in a pastoralist community, Endulen, Tanzania. *PLoS Negl Trop Dis* 2023; 17 (12): e0011855.
 17. Moorthy GS, Madut DB, Kilonzo KG, Lwezaula BF, Mbwasia R, Mmbaga BT, Ngocho JS, Saganda W, Bonnewell JP, **Carugati M**, Egger JR, Hertz JT, Tillekeratne LG, Maze MJ, Maro VP, Crump JA, Rubach MP. Antibacterial utilization for febrile illnesses and laboratory-confirmed bloodstream infections in northern Tanzania. *Open Forum Infect Dis* 2023; 10(8): ofad448.
 18. Evans KB, Harris M, Lee H, Hung F, Alexander BD, **Carugati M**. Antibacterial prophylaxis regimens in adult orthotopic liver transplantation and incidence of post-operative bacterial infections. *Am J Transplant* 2023; 23: S797.
 19. Ni B, Wolfe CR, Arif S, **Carugati M**, Heldman MR, Messina JA, Miller RA, Saullo JL, Baker AW, Maziarz EK. Single-Center Experience with Maribavir for the Treatment of CMV Infection in Solid Organ Transplant Recipients. *Am J Transplant* 2023; 23: S1102.
 20. Villa S, **Carugati M**, Rubach MP, Cleaveland S, Mpagama SG, Khan SS, Mfinanga S, Mmbaga BT, Crump JA, Raviglione MC. One health approach to end zoonotic TB. *Int J Tuberc Lung Dis* 2023; 27 (2): 101-105.
 21. **Carugati M**, Arif S, Sudan DL, Collins BH, Haney JC, Schroder JN, Reynolds JM, Lewis SS, Yarrington ME, Miller RA, Alexander BD. Epidemiology of surgical site infections after solid organ transplants in the period 2015-2019: A single-center retrospective cohort study. *Am J Transplant* 2022; 22 (12): 3021-3030.
 22. Guardia SP, Marin-Corral J, Amati F, Aliberti S, **Carugati M**, Sibila O, et al. Risk factors and guideline adherence of empiric antibiotic use in community-acquired pneumonia. *Eur Resp J* 2022; 60: S66: 4255.
 23. Cutting ER, Simmons RA, Madut DB, Maze MJ, Kalengo NH, **Carugati M**, Mbwasia RM, Kilonzo KG, Lyamuya F, Marandu A, Mosha C, Saganda W, Lwezaula BF, Hertz JT, Morrissey AB, Turner EL, Mmbaga BT, Kinabo GD, Maro VP, Crump JA, Rubach MP. Facility-based disease surveillance and Bayesian hierarchical modeling to estimate endemic typhoid fever incidence, Kilimanjaro Region, Tanzania, 2007-2018. *PLoS Negl Trop Dis* 2022; 16 (7): e0010516.

24. Costales C, Crump JA, Mremi A, Amsi P, Kalengo N, Kilonzo KG, Kinabo GD, Lwezaula BF, Lyamuya F, Marandu A, Mbwas R, Mmbaga BT, Mosha C, **Carugati M**, Madut DB, Nelson A, Maze MJ, matkovic E, Zaki S, Maro VP, Rubach MP. Performance of Xpert Ultra nasopharyngeal swab for identification of tuberculosis deaths in northern Tanzania. *Clin Microbiol Infect* 2022; 28 (8): 1150.e1-1150.e6.
25. Pisharody S, Rubach MP, **Carugati M**, Nicholson WL, Perniciaro JL, Biggs HM, Maze MJ, Hertz JT, Halliday JEB, Allan KJ, Mmbaga BT, Saganda W, Lwezaula BF, Kazwala RR, Cleaveland S, Maro VP, Crump JA. Incidence estimates of acute Q fever and Spotted Fever Group Rickettsioses, Kilimanjaro, Tanzania, from 2007 to 2008 and from 2012 to 2014. *Am J Trop Med Hyg* 2021; 106: 494-503.
26. Bonnewell JP, Rubach MP, Madut DB, **Carugati M**, Maze MJ, Kilonzo KG, Lyamuya F, Marandu A, Kalengo NH, Lwezaula BF, Mmbaga BT, Maro VP, Crump JA. Performance assessment of Universal Vital Assessment score vs other severity scores for predicting risk of in-hospital death among adult febrile inpatients in northern Tanzania, 2016-2019. *JAMA Netw Open* 2021; 4: e2136398.
27. Zhuang Y, Zahari M, Mah M, Chen YH, Crump JA, **Carugati M**, Maze MJ, Bonnewell JP, Madut DB, Lwezaula BF, Mmbaga BT, Maro VP, Smith G, Linster M, Rubach MP. Respiratory pathogen detection among febrile inpatients in northern Tanzania, 2016-2019. *Am J Trop Med Hyg* 2021; 105 (S5): 400.
28. Madut DB, Rubach MP, Bonnewell JP, Cutting ER, **Carugati M**, Kalengo N, Maze MJ, Morrissey AB, Mmbaga BT, Lwezaula BF, Kinabo GD, Mbwas R, Kilonzo KG, Maro VP, Crump JA. Trends in fever case management for febrile inpatients in a low malaria incidence setting of Tanzania. *Trop Int Health* 2021; 26: 1668-1676.
29. Maze MJ, Elrod MG, Biggs HM, Bonnewell J, **Carugati M**, Hoffmaster AR, Lwezaula BF, Madut DB, Maro VP, Mmbaga BT, Morrissey AB, Saganda W, Sakasaka P, Rubach MP, Crump JA. Investigation of melioidosis using blood culture and indirect hemagglutination assay serology among patients with fever, northern Tanzania. *Am J Trop Med Hyg* 2020; 103: 2510-2514.
30. Zhuang Y, Mah MKY, Chen Y, Crump YA, **Carugati M**, Bonnewell JP, Maro VP, Smith G, Linster M, Rubach MP. Respiratory pathogens in a febrile cohort from Tanzania and associated risks for severe disease outcome. *Int J Infect Dis* 2020; 101 (S1): 367.
31. Guardia SP, Marin-Corral J, **Carugati M**, Aliberti S, Sibila O, Sanz F, Sotgiu G, Marcos PJ, Kolditz M, Restrepo MI. International guideline concordance of empiric antibiotic use in community-acquired pneumonia. *Eur Resp J* 2020; 56 (S64): 4669.
32. Restrepo MI, Pascual-Guardia S, Marin-Corral J, Carugati M, Rodriguez A, Sibila O, Sanz F, Sotgiu G, Kolditz M, Aliberti S. Anti-Pseudomonas antibiotic use for hospitalized patient with community-acquired pneumonia. *Eur Resp J* 2020; 56 (S64): 3094.
33. **Carugati M**, Piazza A, Peri AM, Cariani L, Brilli M, Girelli D, Di Carlo D, Gramegna A, Pappalettera M, Comandatore F, Grasselli G, Cantù AP, Arghittu M, Gori A, Bandi C, Blasi F, Bandera A; IFALT working group. Fatal respiratory infection due to ST308 VIM-1-producing *Pseudomonas aeruginosa* in a lung transplant recipient: case report and review of the literature. *BMC Infect Dis* 2020; 20:635.
34. Marin-Corral J, Pascual-Guardia S, Francesco A, Aliberti S, Masclans JR, Soni N, Rodriguez A, Sibila O, Sanz F, Sotgiu G, Anzueto A, Dimakou K, Petrino R, van de Garde E, Restrepo MI; **GLIMP investigators**. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized with Community-Acquired Pneumonia. *Chest* 2021; 159: 58-72.
35. Franzetti M, Pozzetti U, **Carugati M**, Pandolfo A, Molteni C, Faccioli P, Castaldo G, Longoni E, Ormas V, Iemoli E, Piconi S. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe coronavirus disease 2019: a case report. *Int J Infect Dis* 2020; 97: 215-218.

36. Peri AM, Piazza A, De Zan V, **Carugati M**, Muscatello A, Comandatore F, De Lorenzis E, Pluderi M, Arghittu M, Cantù AP, Bandi C, Cugno M, Gori A, Bandera A. Autochthonous ST405 NDM-5 producing *Escherichia coli* causing fatal sepsis in Northern Italy. *Int J Antimicrob Agents* 2020; 55: 105953.
37. **Carugati M**, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M, Leuschner P, Ruiz-Buitrago S, Battaglia S, Fantini R, Pascual-Guardia S, Marin-Corral J, Restrepo MI, GLIMP collaborators. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. *Eur J Clin Microbiol Infect Dis* 2020; 39: 1513-1525.
38. **Carugati M**, Morlacchi LC, Peri AM, Alagna L, Rossetti V, Bandera A, Gori A, Blasi F, and IFALT working group. Challenges in the diagnosis and management of bacterial lung infections in solid organ recipients. A narrative review. *Int J Mol Sci* 2020; 21: 1221.
39. Halliday JEB, **Carugati M**, Snaveley ME, Allan KJ, Beamesderfer J, Ladbury GAF, Hoyle DV, Holland P, Crump JA, Cleaveland S, Rubach MP. Zoonotic causes of febrile illness in malaria endemic countries: a systematic review. *Lancet Infect Dis* 2020; 20: e27–37.
40. Madut DB, Rubach MP, Kalengo N, **Carugati M**, Maze MJ, Morrissey AB, Mmbaga BT, Lwezula BF, Kilonzo KG, Maro VP, Crump JA. A prospective study of *Escherichia coli* bloodstream infection among adolescents and adults in northern Tanzania. *Trans R Soc Trop Med Hyg* 2020; 114: 378-384.
41. **Carugati M**, Kilonzo KG, Crump JA. Fever, bacterial zoonoses, and One Health in sub-Saharan Africa. *Clin Med* 2019; 19: 375-380.
42. Aliberti S, Cook GS, Babu BL, Reyes LF, H Rodriguez A, Sanz F, Soni NJ, Anzueto A, Faverio P, Sadud RF, Muhammad I, Prat C, Vendrell E, Neves J, Kaimakamis E, Feneley A, Swarnakar R, Franzetti F, **Carugati M**, Morosi M, Monge E, Restrepo MI; GLIMP investigators. International prevalence and risk factors evaluation for drug resistant *Streptococcus pneumoniae* pneumonia. *J Infect* 2019; 79: 300-311.
43. Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, González Del Castillo J, Blasi F, Aliberti S, Restrepo MI; **GLIMP investigators**. Prevalence and etiology of community acquired pneumonia in immunocompromised patients. *Clin Infect Dis* 2019; 68: 1482-1493.
44. Restrepo MI, Borsa N, **Carugati M**, Soni N, Rodriguez A, Blasi F, Aliberti S. MRSA specific scores promote overuse of anti-MRSA antibiotics. *Eur resp J* 2019; 54: 63.
45. Foresti S, Perego MR, **Carugati M**, Casati A, Malafronte C, Manzoni M, Badolato R, Gori A, Achilli F. The hidden hypothesis: a disseminated tuberculosis case. *Int J Infect Dis* 2019; 85: 88-91.
46. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, **Carugati M**, Holland TL, Fowler VG Jr. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol* 2019; 17: 203-218.
47. Vanoni NM, **Carugati M**, Borsa N, Sotgiu G, Saderi L, Gori A, Mantero M, Aliberti S, Blasi F. Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review. *Med Sci* 2019 14; 7(1).
48. Costales C, Rubach MP, Mremi A, Amsi P, **Carugati M**, Nelson AM, Maro VP, Crump JA. Assessing the role of post-mortem microbiology in determining the cause of fatal febrile illness, Kilimanjaro, Tanzania. *Am J Med Hyg* 2019; 101: 146.
49. Cutting ER, Madut DB, Maze MJ, Kalengo NH, **Carugati M**, Mmbaga BT, Mbwas RM, Kilonzo KG, Marandu A, Mosha C, Lyamuya F, Kinabo GD, Morrissey AB, Maro VP, Rubach MP, Crump JA. Endemic typhoid incidence, Kilimanjaro region, Tanzania, 2007-2018. *Am J Trop Med Hyg* 2019; 101: 331.

50. **Carugati M**, Aliberti S, Reyes LF, Franco Sadud R, Irfan M, and Prat C, Soni NJ, Faverio P, Gori A, Blasi F, Restrepo MI. Microbiological testing of adults hospitalized with community-acquired pneumonia: an international study. *ERJ Open Research* 2018; 4 (4).
51. Radavanovic D, Sotgiu G, Jankovic M, Mahesh PA, Marcos PJ, Abdalla MI, Di Pasquale MF, Gramegna A, Terraneo S, Blasi F, Santus P, **Carugati M**, Aliberti S, Reyes LF, Restrepo MI. An international perspective on hospitalized patients with viral community-acquired pneumonia. *Eur J Intern Med* 2018; 60: 54-70.
52. Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chaffari AM, Chow SC, Chu VH, **Carugati M**, Cook P, Corey GR, Crowley AL, Daly J, Gu J, Hachem R, Horton J, Jenkins TC, Levine D, Miro JM, Pericas JM, Riska P, Rubin Z, Rupp ME, Schrank J Jr, Sims M, Wray D, Zervos M, Fowler VG. Staphylococcal Bacteremia Investigators. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. *JAMA* 2018; 320: 1249-1258.
53. Mmbaga BT, Mremi A, Amsi P, Emmanuel M, Kalengo N, **Carugati M**, Maro VP, Crump JA, Maugau L, Kondo C, Rubach MP. Etiologies of gastro-intestinal perforations in Kilimajaro, Tanzania. Prospective hospital-based sentinel surveillance. *Am J Trop Med Hyg* 2018; 99: 163.
54. **Carugati M**, Zhang HL, Kilonzo KG, Maze MJ, Maro VP, Rubach MP, Crump JA. Predicting Mortality for Adolescent and Adult Patients with Fever in Resource-Limited Settings. *Am J Trop Med Hyg* 2018; 99: 1246-1254.
55. Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S; **GLIMP collaborators**. Burden and risk factors for *Pseudomonas aeruginosa* community-acquired pneumonia: a multinational point prevalence study of hospitalized patients. *Eur Resp J* 2018; 52. pii: 1701190.
56. **Carugati M**, Biggs HM, Maze MJ, Stoddard RA, Cash-Goldwasser S, Hertz JT, Halliday JEB, Saganda W, Lwezaula BF, Kazwala RR, Cleaveland S, Maro VP, Rubach MP, Crump JA. Incidence of Human Brucellosis in the Kilimanjaro Region of Tanzania in the Periods 2007-2008 and 2012-2014. *Trans Royal Soc Trop Med & Hyg* 2018; 112: 136-143.
57. Aliberti S, Ramirez JC, Giuliani F, Wiemken TL, Sotgiu G, Tedeschi S, **Carugati M**, Valenti V, Marchioni M, Camera M, Piro R, Del Forno M, Milani G, Faverio P, Richeldi L, Deotto M, Villani M, Voza A, Tobaldini E, Bernardi M, Bellone A, Bassetti M, Blasi F. Individualizing duration of antibiotic therapy in community-acquired pneumonia. *Pulmonary Pharmacology and Therapeutics*. DOI: 10.1016/j.pupt.2017.06.008
58. Pericas J, Messina J, Garcia-de-la-Maria C, Park L, Sharma-Kuinkel B, Marco F, Wray D, Kanafani Z, **Carugati M**, Durante Mangoni E, Tattevin P, Chu VH, Moreno MA, Fowler VG, Miro J. Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible *Staphylococcus aureus* Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis. *Clin Microbiol Infect* 2017; 23: 544-549.
59. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI, **Carugati M**, Franzetti F, and GLIMP investigators. Global initiative for methicillin-resistant *Staphylococcus aureus* pneumonia (GLIMP): an international, observational cohort study. *Lancet Infect Dis*. 2016;16:1364-1376.
60. **Carugati M**, Petti CA, Arnold C, Miro J, Pericàs J, Garcia de la Maria C, Kanafani Z, Durante-Mangoni E, Baddley J, Wray D, Klein JL, Delahaye F, Fernandez-Hidalgo N, Hannan MM, Murdoch D, Bayer A, Chu VH. Antistaphylococcal β -lactams vs. vancomycin for the treatment of infective endocarditis due to methicillin-susceptible coagulase-negative staphylococci. A prospective cohort study from the International Collaboration on Endocarditis (ICE). *Antimicrob Agents Chemother* 2016; 60: 6341-6349.

61. **Carugati M**, Franzetti F, Wiemken T, Kelly R, Peyrani P, Blasi F, Ramirez J, Aliberti S. De-escalation therapy among bacteremic patients with community-acquired pneumonia. *Clin Microbiol Infect* 2015; 21: 11-18.
62. Schirotti C, **Carugati M**, Zanini F, Bandera A, Di Nardo Stuppino S, Monge E, Morosi M, Gori A, Matteelli A, Codecasa L, Franzetti F. Exogenous reinfection of tuberculosis in a low burden area. *Infection* 2015; 43 (6): 647-653.
63. Aliberti S, Giuliani F, Bonaiti G, Faverio P, **Carugati M**, Spoletini G, Fantini R, Tedeschi S, Milani G, Villani M, Del Forno M, Piro R, Deotto M, Pancini L, Voza A, Ramirez J, Blasi F. How to choose the duration of antibiotic therapy in patients with pneumonia. *Curr Opin Infect Dis* 2015; 28:177-184.
64. **Carugati M**, Schirotti C, Zanini F, Vanoni N, Galli M, Adorni F, Franzetti F. A new predictive model to improve respiratory isolation strategy in HIV patients with pulmonary tuberculosis. *Int J Tub Lung Dis* 2014; 18: 831-836.
65. Zanini F, **Carugati M**, Schirotti C, Lapadula G, Lombardi A, Codecasa L, Gori A, Franzetti F. *Mycobacterium tuberculosis* Beijing family: analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan. *Infection, Genetics and Evolution* 2014; 25: 14-19.
66. Lapadula G, Zanini F, Codecasa L, Franzetti F, Ferrarese M, **Carugati M**, Mazzola E, Schirotti C, Motta D, Iemmi D, Gori A. Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering. *Mediterr J Hematol Infect Dis* 2013; 5.
67. **Carugati M**, Bayer AS, Miró JM, Park LP, Guimarães AC, Skoutelis A, Fortes CQ, Durante-Mangoni E, Hannan MM, Nacimovich F, Fernández-Hidalgo N, Grossi P, Tan RS, Holland T, Fowler VG, Corey RG, Chu VH. High-dose daptomycin therapy for left-sided infective endocarditis. A prospective study from the International Collaboration on Endocarditis (ICE). *Antimicrob Agents Chemother.* 2013; 57: 6213-6222.
68. **Carugati M**, Franzetti M, Torre A, Giorgi R, Genderini A, Strambio de Castilla F, Gervasoni C, and Riva A. Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. *Clin Rheumatol* 2013; 32: 1399-1405.
69. **Carugati M**, Aliberti S, Franzetti F. Should health care system and health care providers implement a new pathway for hospitalized patients with community acquired pneumonia? *Arch Intern Med* 2012; 172: 1771.
70. **Carugati M**, Zanini F, Schirotti C, Gori A and Franzetti F. MIRU–VNTR and Beijing/W family of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* 2011, 49: 2780-2781.

PUBBLICAZIONI SCIENTIFICHE PEER-REVIEWED EDITE A STAMPA PECULIARMENTE SIGNIFICATIVE AI FINI DELLA VALUTAZIONE

Tutte le pubblicazioni sopra riportate sono significative ai fini della valutazione. A seguire riporto le pubblicazioni piu' rilevanti ed un breve commento circa il loro impatto scientifico.

Carugati M, Arif S, Reynolds JM, Haney JC, Yarrington ME, Young K, Kulkarni D, Benjamin A, Walline K, Huggins J, Rosser M, Morrison S, Peskoe S, Bottiger BA, Miller RA, Alexander BD. Invasive surgical site infections after lung transplantation: contemporary risk factors and associated clinical outcomes. J Heart Lung Transplant Open 2025. Accettato il 16 Maggio 2025 (JHLTO_100294).

Le infezioni invasive del sito chirurgico dopo trapianto di polmone influenzano negativamente il decorso post-trapianto (graft failure and 1-year mortality). Analisi contemporanea e rigorosa dei fattori di rischio per infezioni invasive del sito chirurgico condotta presso uno dei maggiori centri trapianto di polmone al mondo.

Tam PCK, Messina JA, Bin N, Heldman MR, Steinbrink JM, Reynolds JM, DeVore AD, Baker AW, **Carugati M**, Schwartz IS, Wolfe CR. HOPE in every breath and heartbeat: Understanding transplant eligibility, access barriers, and clinical outcomes in thoracic transplantation in persons with HIV. J Heart Lung Transplant Open 2025.

Studio retrospettivo di coorte circa trapianto di organi toracici in persone con infezione da HIV: disamina del percorso trapiantologico e degli esiti post-trapianto. Si tratta una delle poche esperienze di trapianto di organi toracici in pazienti con infezione da HIV disponibili in letteratura.

Carugati M, Arif S, Yarrington ME, King LY, Harris M, Evans K, Barbas AS, Sudan DL, Miller RA, Alexander BD. Risk Factors for Invasive Surgical Site Infections among Adult Single Liver Transplant Recipients at Duke University Hospital in the Period 2015-2020. Transplantation Direct 2024. 10.1097/TXD.0000000000001719.

Analisi dei fattori di rischio per infezioni invasive del sito chirurgico in pazienti adulti sottoposti a trapianto epatico. Lavoro multidisciplinare che ha coinvolto infettivologi, farmacologi clinici e chirurghi e che e' risultato in una modifica data-driven del protocollo di Duke University di profilassi peri-operatoria per trapianto epatico.

Ni B, Wolfe CR, Arif S, **Carugati M**, Heldman MR, Messina JA, Miller RA, Saullo JL, Baker AW, Maziarz EK. Real-World Experience with Maribavir for the Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infect Dis 2024; 11 (7): ofae335.

Una delle prime esperienze post-trial circa utilizzo di maribavir nel trattamento di infezioni da CMV in pazienti sottoposti a trapianto di organo solido. Risultati critici, evidenziando i limiti di maribavir nel trattamento delle alte viremie.

Carugati M, Arif S, Sudan DL, Collins BH, Haney JC, Schroder JN, Reynolds JM, Lewis SS, Yarrington ME, Miller RA, Alexander BD. Late Surgical Site Infections among Solid Organ Transplant Recipients: An Unrecognized Clinical Entity. *Infection Prevention and Control* 2024; 24: 1-5.

In questo articolo vengono riportate infezioni del sito chirurgico post-trapianto di organi solidi (addominali e toracici) occorrenti dopo i canonici 90 giorni indicati dai CDC per la sorveglianza delle infezioni del sito chirurgico. Questi dati mettono in discussione la validità della definizione proposta dai CDC.

Carugati M, Arif S, Yarrington ME, King LY, Harris M, Evans K, Barbas AS, Sudan DL, Perfect JR, Miller RA, Alexander BD. Limitations of Antifungal Prophylaxis in Preventing Invasive *Candida* Surgical Site Infections after Liver Transplant Surgery. *Antimicrobial Agents and Chemotherapy* 2024; 68 (3): e0127923.

Analisi dei limiti della profilassi antifungina nel prevenire infezioni invasive del sito chirurgico da Candida spp. dopo trapianto epatico. Questo lavoro suggerisce una limitata penetrazione delle echinocandine nella cavità peritoneale, confermando risultati simili circa la penetrazione delle echinocandine nella cavità pleurica. Importanti implicazioni cliniche.

Carugati M, Arif S, Sudan DL, Collins BH, Haney JC, Schroder JN, Reynolds JM, Lewis SS, Yarrington ME, Miller RA, Alexander BD. Epidemiology of surgical site infections after solid organ transplants in the period 2015-2019: A single-center retrospective cohort study. *Am J Transplant* 2022; 22 (12): 3021-3030.

Questo studio viene considerato pietra miliare per la conoscenza delle infezioni del sito chirurgico post trapianto di organo solido. I tassi di infezione del sito chirurgico riportati in questo lavoro vengono considerati come benchmark di qualità per centri trapianto.

Halliday JEB, **Carugati M**, Snaveley ME, Allan KJ, Beamesderfer J, Ladbury GAF, Hoyle DV, Holland P, Crump JA, Cleaveland S, Rubach MP. Zoonotic causes of febrile illness in malaria endemic countries: a systematic review. *Lancet Infect Dis* 2020; 20: e27-37.

Revisione sistematica delle cause di febbre in paesi dove malaria è endemica. I risultati presentati sottolineano le molteplici eziologie infettive di febbre anche in paesi dove la malaria è endemica. Da qui lo slogan 'non tutte le febbri sono malaria' diffuso a scopo educativo sulle reti radiofoniche della Tanzania. Lavoro rigoroso pubblicato su Lancet Infectious Diseases.

Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, **Carugati M**, Holland TL, Fowler VG Jr. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol* 2019; 17: 203-218.

Sintesi della ricerca clinica e di base su Staphylococcus aureus. L'importanza di questo lavoro è evidenziata dalla sua pubblicazione su Nature Reviews Microbiology e soprattutto dalle 1966 citazioni ricevute.

Costales C, Rubach MP, Mremi A, Amsi P, **Carugati M**, Nelson AM, Maro VP, Crump JA. Assessing the role of post-mortem microbiology in determining the cause of fatal febrile illness, Kilimanjaro, Tanzania. *Am J Trop Med Hyg* 2019; 101: 146.

Risultati preliminari dello studio INDITe (Investigating Febrile Deaths in Tanzania) sponsorizzato da NIH e condotto con l'apporto di US CDC (Dr. Sherif Zafi, Infectious Diseases Pathology branch). Questo studio ha richiesto la creazione pressoché ex novo di una unità di anatomia patologica presso Kilimanjaro Christian Medical Center (Moshi, Tanzania) ed un lungo lavoro culturale per l'accettazione di autopsie in Africa sub-Sahariana. Risultati finali in via di pubblicazione.

Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chافتari AM, Chow SC, Chu VH, **Carugati M**, Cook P, Corey GR, Crowley AL, Daly J, Gu J, Hachem R, Horton J, Jenkins TC, Levine D, Miro JM, Pericas JM, Riska P, Rubin Z, Rupp ME, Schrank J Jr, Sims M, Wray D, Zervos M, Fowler VG. Staphylococcal Bacteremia Investigators. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. *JAMA* 2018; 320: 1249-1258.

Trial randomizzato controllato per la definizione della durata di trattamento delle batteriemie da Staphylococci aureus e coagulase negativi. Pubblicazione su JAMA seguita da implementazione clinica world-wide.

Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI, and GLIMP investigators (tra cui **Carugati M**). Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. *Lancet Infect Dis*. 2016;16:1364-1376.

Point-prevalence study per determinare incidenza di MRSA come causa di polmoniti in pazienti ospedalizzati. Risultati importanti per ridurre la prescrizione di farmaci anti-MRSA in contesti a bassa incidenza e prova di capacità di collaborazione internazionale (Università degli Studi di Milano e Duke University entrambe partecipano).

Carugati M, Petti CA, Arnold C, Miro J, Pericàs J, Garcia de la Maria C, Kanafani Z, Durante-Mangoni E, Baddley J, Wray D, Klein JL, Delahaye F, Fernandez-Hidalgo N, Hannan MM, Murdoch D, Bayer A, Chu VH. Antistaphylococcal β -lactams vs. vancomycin for the treatment of infective endocarditis due to methicillin-susceptible coagulase-negative staphylococci. A prospective cohort study from the International Collaboration on Endocarditis (ICE). *Antimicrob Agents Chemother* 2016; 60: 6341-6349.

I risultati di questo studio affrontano e ridimensionano il problema della etero-resistenza nel trattamento delle infezioni endovascolari da staphylococchi coagulasi negativi.

Carugati M, Bayer AS, Miró JM, Park LP, Guimarães AC, Skoutelis A, Fortes CQ, Durante-Mangoni E, Hannan MM, Nacinovich F, Fernández-Hidalgo N, Grossi P, Tan RS, Holland T, Fowler VG, Corey RG, Chu VH. High-dose daptomycin therapy for left-sided infective endocarditis. A prospective study from the International Collaboration on Endocarditis (ICE). *Antimicrob Agents Chemother.* 2013; 57: 6213-6222.

Nel 2006 NEJM pubblica un trial che dimostra efficacia e sicurezza di daptomicina nel trattamento di batteriemie ed endocarditi del cuore destro da Staphylococcus aureus. Questo lavoro completa i risultati del NEJM trial valutando l'utilizzo di daptomicina per il trattamento di endocarditi del cuore sinistro.

INDICATORI DI PRODUTTIVITA' E QUALITA' SCIENTIFICA (dati ottenuti da Google Scholar e Scopus)

- Numero di citazioni (Google Scholar): 3659
- Percentuale delle pubblicazioni comprese nel 25% dei manoscritti piu' citati al mondo (Scopus): 40%
- Percentuale delle pubblicazioni nel 25% delle top riviste per CiteScore (Scopus): 71.8%
- H-index (Google Scholar): 21
- Impact factor personale negli ultimi 5 anni (calcolo eseguito in Scopus)

Anno	Impact factor
2020	190
2021	32.2
2022	14.1
2023	8.3
2024	4.2
2020-2024	49.8 (media)

Manuela Carugati, MD

23 Maggio, 2025